Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications

Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications

Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P =. 73), drug intolerability (1/5 vs 4/11; P = 1), or...

Full description

Bibliographic Details
Main Authors: Aleissa, M.M (Author), Cheng, M.P (Author), Gonzalez-Bocco, I.H (Author), Koo, S. (Author), Manne-Goehler, J. (Author), Marty, F.M (Author), Zhou, E. (Author)
Format: Article
Language:English
Published: Oxford University Press 2022
Subjects:
alanine aminotransferase
area under the curve
Article
atypical Mycobacterium
azithromycin
body weight loss
cancer growth
clarithromycin
constipation
controlled study
drug efficacy
drug interaction
drug metabolism
drug safety
glutathione peroxidase
graft versus host reaction
hearing impairment
hematologic malignancy
human
immunocompromised host
immunocompromised patient
liver function test
mortality
Mycobacterium avium complex
nonhuman
nontuberculous mycobacteria
overall survival
primary sclerosing cholangitis
retrospective study
rheumatoid arthritis
rifampicin
ritonavir
ruxolitinib
Sjoegren syndrome
thrombocytopenia
toxic hepatitis
vomiting
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items